Retraction Note: Xia-yu-xue decoction (XYXD) reduces carbon tetrachloride (CCl4)-induced liver fibrosis through inhibition hepatic stellate cell activation by targeting NF-κB and TGF-β1 signaling pathways
BMC Complementary Medicine and Therapies volume 22, Article number: 236 (2022)
Retraction Note: BMC Complement Altern Med 15, 201 (2015)
The Editor has retracted this article. After publication, concerns were raised regarding western blot image similarities between Fig. 3B in this article and Fig. 3C in another article with one shared author  that was under consideration within a close time frame.
Additionally, the JNK blots in Fig. 3B are presented upside-down, and there appear to be unexplained breaks in the western blot backgrounds in Fig. 4B.
The authors have been unable to provide the original blots from the experiments reported in this article. The Editor therefore no longer has confidence in the presented data.
Author Zhuoan Cheng agrees to this retraction. Author Cheng Liu has not explicitly stated whether they agree to this retraction notice. Authors Xia Yuan, Le Tao, Zhuoan Cheng, Xiuqin Dai, Xia Sheng and Dongying Xue have not responded to any correspondence from the editor or publisher about this retraction.
Liu C, Yang Z, Wang L, et al. Combination of sorafenib and gadolinium chloride (GdCl3) attenuates dimethylnitrosamine(DMN)-induced liver fibrosis in rats. BMC Gastroenterol. 2015;15:159. https://doi.org/10.1186/s12876-015-0380-5.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Liu, C., Yuan, X., Tao, L. et al. Retraction Note: Xia-yu-xue decoction (XYXD) reduces carbon tetrachloride (CCl4)-induced liver fibrosis through inhibition hepatic stellate cell activation by targeting NF-κB and TGF-β1 signaling pathways. BMC Complement Med Ther 22, 236 (2022). https://doi.org/10.1186/s12906-022-03714-x